About

Copious research efforts have been undertaken in MS research in the last three decades to unravel immune mechanisms in the periphery thought to be responsible for disease onset and effector mechanisms mediating CNS damage.  However, the underlying molecular causes of MS are still not understood and prognostic estimates can hardly be given to patients in the absence of valid surrogate markers.  Traditional therapeutic disease modifying regimens aim at immunomodulation or immunosuppression and were developed in the context of autoimmune research in conjunction with other diseases such as rheumatoid arthritis, Crohn’s disease and diabetes mellitus.  However, response to anti-inflammatory therapeutic interventions differs significantly between MS and other autoimmune disorders.  Moreover, in many MS patients, response to the current interventions has only limited impact on disease progression.  Finally, novel therapies in MS aimed at reducing the CNS-directed immune responses are associated with a severe risk for opportunistic CNS infection.

There is currently an urgent need to go back to basics and apply completely novel ideas and unconventional methods as well as brand new technologies to research in this area.  Now is the time to take up the challenge and, for the first time in Germany, promote interaction between strong research groups at three different sites that all have the ideal prerequisites for illuminating and expanding highly novel and innovative perspectives in MS research.  The goal of this consortium, which consists of scientists from centers in the Rhine-Main area, Münster and Munich, is to unravel the pathology of MS and develop as well as understand novel therapeutic concepts.  The ideal prerequisites for such progress are provided by effectively linking scientists from neighboring disciplines with classical neuroimmunologists, who possess a proven track record in MS research and patient care and arise from an important and internationally visible nucleus in this field.  One key aspect here is the strong bidirectional crosstalk between pure experimental research in animal models and clinical research in human systems and patients, which allows the best transfer of basic knowledge into clinical care – and vice versa.

News

Tue, 22/10/2019
The key lies in cell metabolism: Neuroscientist and neurologist Luisa Klotz wins renowned Heinrich-Pette-Award
Münster. For the third time the renowned neuroscience award “Heinrich Pette prize” goes to Münster, as this year Luisa Klotz was rewarded with the prestigious award for neuroscience researchers and clinicians at the congress of the German Society of Neurology in Stuttgart. Neurologist and Neuroscientist Luisa Klotz received the award for her outstanding research in […]...more
Mon, 07/10/2019
Talk “Der Einfluss der Ernährung und des Darms auf die Multiple Sklerose”
Muenster. The department of neurology with Institute of Translational Neurology warmly welcomes SFB 128-PI Prof. Aiden Haghikia, leading senior physician at the Department of Neurology at Bochum University Clinic. His talk “Der Einfluss der Ernährung und des Darms auf die Multiple Sklerose” provides insights into his latest research progress in this field. Time: Wednesday, October […]...more
Mon, 03/06/2019
Publication: Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects.
Muenster. For the first time scientists from the University of Münster could show that multiple sclerosis (MS) alters the energy metabolism of T cells during acute phases of disease exacerbation. Therapeutic interventions targeting the metabolism of activated T cells display new potential avenues for treatment of patients with MS affecting around 250,000 people in Germany. The […]...more